Human CD45RO Alexa Fluor® 350-conjugated Antibody Summary
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, 2 to 8 °C as supplied.
Background: CD45RO
CD45, previously called LCA (leukocyte common antigen), T200, or Ly5 in mice, is member C of the class 1 (receptor‑like) protein tyrosine phosphatase family (PTPRC) (1, 2). It is a variably glycosylated 180-220 kDa transmembrane protein that is abundantly expressed on all nucleated cells of hematopoietic origin (1-3). Multiple splicing isoforms of exon 4 (A), 5 (B), and 6 (C) are expressed according to cell type, developmental stage and antigenic exposure (1-5). The longest form, CD45RABC (called B220 in mouse) is expressed on B lymphocytes, The shortest form, CD45R0, lacking exons 4, 5 and 6 which encode aa 34‑194, is expressed on memory cells, while intermediate sizes are expressed on other T cells (3, 4, 6). Human CD45 has a 40% and 41% sequence identity with mouse and rat respectively. The CD45R0 cDNA encodes 1145 amino acids (aa), including a 25 aa signal sequence, a 391 aa extracellular domain, 21 aa transmembrane sequence, and a 708 aa cytoplasmic domain that contains two phosphatase domains, D1 and D2. Only D1 has phosphatase activity. CD45 has been best studied in T cells, where it determines T cell receptor signaling thresholds (3, 6‑8). CD45 is moved into or out of the immunological synapse (IS) membrane microdomain depending on the relative influence of interaction with the extracellular galectin lattice or the intracellular actin cytoskeleton (9, 10). Galectin interaction can be fine‑tuned by varying usage of the heavily O‑glycosylated spliced regions and sialylation of N‑linked carbohydrates (4, 9). Within the IS, CD45 dephosphorylates and negatively regulates the Src family kinase, Lck (8‑10). In other leukocytes, CD45 influences differentiation and links immunoreceptor signaling with cytokine secretion and cell survival, partially overlapping in function with DEP‑1/CD148 (11‑14). CD45 deletion causes in severe immunodeficiency, while point mutations may be associated with autoimmune disorders (6, 7).
- Anderson, J.N. et al. (2004) FASEB J. 18:8.
- Streuli, M. et al. (1987) J. Exp. Med. 166:1548.
- Hermiston, M.L. et al. (2003) Annu. Rev. Immunol. 21:107.
- Earl, L.A. and L.G. Baum (2008) Immunol. Cell Biol. 86:608.
- Ralph, S.J. et al. (1987) EMBO J. 6:1251.
- Falahti, R. and D. Leitenberg (2008) J. Immunol. 181:6082.
- Tchilian, E.Z. and P.C.L. Beverley (2006) Trends Immunol. 27:146.
- McNiell, L. et al. (2007) Immunity 27:425.
- Chen, I-J. et al. (2007) J. Biol. Chem. 282:35361.
- Freiberg, B.A. et al. (2002) Nat. Immunol. 3:911.
- Zhu, J.W. et al. (2008) Immunity 28:183.
- Huntington, N.D. et al. (2006) Nat. Immunol. 7:190.
Product Datasheets
Product Specific Notices
This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Human CD45RO Alexa Fluor® 350-conjugated Antibody
There are currently no reviews for this product. Be the first to review Human CD45RO Alexa Fluor® 350-conjugated Antibody and earn rewards!
Have you used Human CD45RO Alexa Fluor® 350-conjugated Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
